Sign in
CompletedNo phase

Post-Market Clinical Follow-up Study with ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT

Key facts

Who runs it
Straub Medical AG
Where
Austria, France, Germany, Ireland, and Italy9 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
81 people enrolled
Started
3 Apr 2017
Ended
6 Jun 2024
Type of study
Observational
Record updated
3 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Acute thrombotic or thromboembolic occlusion (onset of pain < 14 days)
  • Age > 18 years
  • Written informed consent form

Who cannot take part

  • Known, unhealed pre-existing mechanical damage to the vessel wall, especially caused by surgical procedures or interventional complications
  • Current participation in any other clinical study (medicinal, medical device) or within the last 30 days prior to screening
  • Known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure
  • Severe coagulatory disorders
  • Known or suspected infection, especially of the puncture site or the vessel segment being treated
  • Patient not suitable for thrombectomy
  • Fracture area of broken stents
  • Persistent vasospasm
  • Patients with thrombophilia
  • Aneurysmatically altered vessel segments on target zone or on passage of catheter
  • Immature or not fully healed dialysis accesses or bypass grafts
  • Female subjects of childbearing capacity who are not willing to employ contraceptive measures
  • Pregnant or breast feeding subjects
  • Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study
  • Subjects who are lawfully kept in an institution
  • Subjects who do not have the mental or physical ability to comply with time schedules and further study procedures

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The ASPIREX®S Endovascular System is a rotating and aspirating catheter system. It is intended to be used for the percutaneous transluminal removal of fresh thrombotic or thromboembolic material from native blood vessels (or vessels fitted with stents, stent grafts or native or artificial bypasses) outside the cardiopulmonary, coronary and cerebral circulations.

Read full original descriptionShow less

CAPTUREX® , a catheter with a filter basket, is intended to be used for the filtering of emboli from blood vessels during potentially embolizing procedures on the patient.

ASPIREX®S and CAPTUREX® are CE-marked (Class III) medical devices. In this study the effectiveness and safety in the removal of thrombi in veins is assessed under real life setting.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-Market Clinical Follow-up Study with the ASPIREX®S Endovascular System to Assess the Safety and Effectiveness in the Treatment of DVT Patients and Special Patient Groups
Record updated
3 December 2024